Cannabis terpenes are widely recognized for shaping the plant's aromatic and sensory profiles. Yet, their pharmacological role in cannabis is less established. Recent work demonstrated that several cannabis terpenes can activate cannabinoid receptors type 1 and 2 (CB1R and CB2R) as low-efficacy agonists, raising the possibility that they may also modulate the activation at these receptors by...
Introduction Cannabis consumption has rapidly increased in Delaware due to the legalization of recreational use. There is limited research, however, investigating the links between cannabis use and cognition in older adults. Objectives The objective of this study is to represent the first population-level analysis of cannabis use and subjective cognitive decline (SCD) in older adults in First...
Introduction The expanding use of cannabis, in both recreational and medicinal contexts, highlights a dual reality of therapeutic potential and clinical concern. On one side, cannabinoids show promising medical applications, including chronic pain relief and antiemetic effects. On the other, cannabis consumption is linked to a broad spectrum of adverse outcomes. Psychiatric effects range from...
European PsychiatryJune 1, 2026L. Jishkariani, D. Zurabashvili, K. Gigolashvili et al.
Introduction Cannabis decriminalization raises concerns about its psychiatric impact, particularly on psychosis risk. As cannabis became decriminalized in Georgia in 2018, questions emerged regarding changes in substance-related and acute psychotic disorders. Examining these trends is essential to guide prevention, treatment, and policy in a shifting drug landscape. Objectives This study aims...
Introduction Following Thailand’s cannabis decriminalization in 2022, a marked rise in psychiatric presentations related to cannabis use has been observed nationwide. While international evidence has linked high-THC cannabis exposure to psychosis and substance-induced disorders, empirical data from Asian settings remain limited. This late-breaking study provides updated national trends and...
ObjectiveThis study examined stimulant and medicinal cannabis prescribing in individuals before and after referral to an early psychosis (EP) service in Queensland, Australia.MethodsA retrospective review of 220 consecutive EP referrals (2019-2023) was conducted, extracting data on stimulant and medicinal cannabis prescriptions from clinical records. Longitudinal prescribing patterns were...
Introduction In India’s context of an unregulated drug supply, psychosis is often attributed to cannabis based on patient history alone. However, the widespread contamination of substances with synthetic cannabinoids, opioids, and novel psychoactive substances (NPS) precipitates severe and atypical psychotic presentations that are frequently misdiagnosed as Cannabis-Induced Psychosis (CIP)....
NeuropharmacologyJune 1, 2026Evan C Smith, Christos Iliopoulos-Tsoutsouvas, Markos-Orestis Georgiadis et al.
Despite being the most prevalently abused illicit drug class, the neurochemical effects of cannabinoids (CBs) in key reward-related brain regions are not fully understood. Here, we used in vivo microdialysis combined with liquid chromatograph mass spectrometry to delineate how single, intraperitoneal injections of delta-9-tetrahydrocannabinol (Δ9-THC), and synthetic partial (AM11101) and full...
Long-chain polyunsaturated fatty acids (LC-PUFAs) are crucial for brain development, with ω-3 species supporting neuronal membrane architecture, synaptogenesis and cognitive maturation, and ω-6 species linking lipid metabolism to neuronal signalling via the endocannabinoid system (ECS), the network of receptors, lipid mediators, and enzymatic pathways that orchestrate neurodevelopmental...
Retail sales of intoxicants, including derived intoxicating cannabis products (DICPs) such as delta-8 tetrahydrocannabinol (THC) and hallucinogenic mushrooms, have rapidly increased throughout the US, despite their sale being federally illegal. This study assessed DICP and hallucinogenic mushroom availability in US smoke shops with differing DICP and psilocybin laws. In May-October 2025, using...